Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
293780
vs
K
KOSPI 200
Over the past 12 months, AptaBio Therapeutics Inc has underperformed KOSPI 200, delivering a return of -26% compared to KOSPI 200's +50% growth.
Stocks Performance
293780 vs KOSPI 200
Performance Gap
293780 vs KOSPI 200
Performance By Year
293780 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AptaBio Therapeutics Inc
Glance View
AptaBio Therapeutics is a South Korean biotech company that develops new drug candidates, with a focus on treatments built around its aptamer-based technology. An aptamer is a short piece of synthetic DNA or RNA that can be designed to bind to a specific target, which can help the company create drugs or diagnostic tools aimed at precise disease pathways. The company is not a large medicine seller with broad consumer products. Its work is mostly early-stage research, preclinical development, and partnerships with other drug makers or research groups. That means its customers are mainly pharmaceutical partners, research collaborators, and, in the future, patients and hospitals if any of its candidates reach the market. It makes money through collaboration payments, licensing deals, and potentially product sales if its programs become approved medicines. What makes AptaBio different is that it sits at the risky, science-heavy end of the drug industry. Instead of manufacturing everyday medicines, it tries to turn a platform technology into a pipeline of targeted therapies and related tools. Success depends on proving that its candidate drugs are safe, effective, and valuable enough for larger partners or regulators to back them.